Literature DB >> 32476961

Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.

Elyse E Lower1, Madison Sturdivant1, Robert P Baughman1.   

Abstract

BACKGROUND: Bothersome symptoms from sarcoidosis can develop in the absence of identified granulomas. These parasarcoidosis complaints can include small fiber neuropathy, diaphoresis, dysautonomia, and fatigue. Similar issues are also encountered in some cancer patients, especially those with onconeural antibodies.
METHODS: Serum was obtained for onconeural antibody testing from sarcoidosis patients with parasarcoidosis symptoms seen at the University of Cincinnati Sarcoidosis clinic during a six month period. Detection of antibodies was performed using an onconeural antibody panel.
RESULTS: A total of 268 patients with sarcoidosis and one or more features suggesting parasarcoidosis symptoms were enrolled in the study. Of these, 60 (22.4%) had one or more positive onconeural antibodies. In a control group of 46 non sarcoidosis patients seen in the interstitial lung disease clinic, there were only three patients with a positive antibody (Chi square=6.143, p=0.0132). A subgroup of sarcoidosis and control patients completed the small fiber neuropathy screening list. Sarcoidosis patients had a significantly higher score than the control patients (sarcoidosis: 7 [0-49] (Median [range] versus non sarcoidosis: 3 [0-31], p=0.0074). However, no significant differences were measured in the SFNL scores for sarcoidosis patients with an onconeural antibody (9 [3-36]) versus without (7 [0-49]).
CONCLUSION: In patients with parasarcoidosis symptoms, approximately 30% have evidence of onconeural antibody production. This may be a potential cause for parasarcoidosis symptoms in some patients. Copyright:
© 2019.

Entities:  

Keywords:  fatigue; onconeural; paraneoplastic; parasarcoidosis; small fiber neuropathy

Mesh:

Substances:

Year:  2019        PMID: 32476961      PMCID: PMC7247090          DOI: 10.36141/svdld.v36i4.8745

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  21 in total

1.  Fatigue in sarcoidosis: American versus Dutch patients.

Authors:  W P E de Kleijn; M D P Elfferich; J De Vries; G J Jonker; E E Lower; R P Baughman; T E King; M Drent
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

2.  The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.

Authors:  Marc A Judson; Ulrich Costabel; Marjolein Drent; Athol Wells; Lisa Maier; Laura Koth; Hidenobu Shigemitsu; Dan A Culver; Jeffrey Gelfand; Dominique Valeyre; Nadera Sweiss; Elliott Crouser; Adam S Morgenthau; Elyse E Lower; Arata Azuma; Mami Ishihara; Shin-Ichiro Morimoto; Tetsuo Tetsuo Yamaguchi; Noriharu Shijubo; Jan C Grutters; Misha Rosenbach; Hui-Ping Li; Paola Rottoli; Yoshikazu Inoue; Antje Prasse; Robert P Baughman; The Wasog Sarcoidosis Organ Assessment Instrument Investigators
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-04-18       Impact factor: 0.670

3.  Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment.

Authors:  Marjon D Elfferich; Patty J Nelemans; Rudolf W Ponds; Jolanda De Vries; Petal A Wijnen; Marjolein Drent
Journal:  Respiration       Date:  2010-04-29       Impact factor: 3.580

4.  Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.

Authors:  Ashley E Brown; Kiran Motaparthi; Sylvia Hsu
Journal:  Dermatol Online J       Date:  2018-01-19

5.  The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis.

Authors:  Elske Hoitsma; Jolanda De Vries; Marjolein Drent
Journal:  Respir Med       Date:  2011-01       Impact factor: 3.415

Review 6.  The three tiers of screening for sarcoidosis organ involvement.

Authors:  Marc A Judson
Journal:  Respir Med       Date:  2016-02-23       Impact factor: 3.415

7.  Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.

Authors:  Hesham Abboud; Ian Rossman; Maureen A Mealy; Eddie Hill; Nicolas Thompson; Aditya Banerjee; John Probasco; Michael Levy
Journal:  J Neurol       Date:  2017-10-03       Impact factor: 4.849

Review 8.  Small fiber neuropathy: A burning problem.

Authors:  Jinny Tavee; Lan Zhou
Journal:  Cleve Clin J Med       Date:  2009-05       Impact factor: 2.321

Review 9.  Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus.

Authors:  Kyle T Amber; Manuel Valdebran; Sergei A Grando
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

Review 10.  Paraneoplastic neurological complications of breast cancer.

Authors:  Ibrahim Fanous; Patrick Dillon
Journal:  Exp Hematol Oncol       Date:  2016-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.